SCHEMBL2834826

SCHEMBL2834826

CC(C)(C)OC(=O)NC(C(=O)c1ccc(Br)cc1F)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 9/20 0.45
S1PR3 Q99500 2/20 0.44
USP30 Q70CQ3 1/20 0.42
LMNA P02545 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MDM2 Q00987 1/20 0.36
DGAT1 O75907 1/20 0.36
TRPA1 O75762 1/20 0.35
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833304 0.88 S1PR3 (0.45) AAK1S1PR3MAPTALDH1A1GAA
SCHEMBL2833200 0.87 AAK1 (0.44) AAK1S1PR3MAPTGAA
SCHEMBL2833350 0.81 S1PR3 (0.50) AAK1S1PR3LMNAHTTNPC1
SCHEMBL2833334 0.80 S1PR3 (0.44) S1PR3KMT2AMEN1ALDH1A1
SCHEMBL2836601 0.79 S1PR3 (0.51) AAK1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL2836317 0.79 S1PR3 (0.40) AAK1S1PR3
SCHEMBL2836695 0.78 S1PR3 (0.41) S1PR3
SCHEMBL2834202 0.78 S1PR3 (0.41) S1PR3MAPTHTTNPC1ALDH1A1
SCHEMBL2837077 0.77 S1PR3 (0.53) AAK1S1PR3LMNAHTTALDH1A1
SCHEMBL2834216 0.76 RAB9A (0.40) S1PR3LMNAMAPTHTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 AAK1 1304/4885S1PR3 2311/4885USP30 3738/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 AAK1 1304/4885S1PR3 2311/4885USP30 3738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.